Cooperative therapeutic effects of androgen ablation and adenovirus-mediated herpes simplex virus thymidine kinase gene and ganciclovir therapy in experimental prostate cancer

Cancer Gene Therapy

Volumn 6, Issue 1, 1999, Pages 54-63

  Hall, Simon J ^a   Mutchnik, Steven E ^a   Yang, Guang ^a   Timme, Terry L ^a   Nasu, Yasutomo ^a   Bangma, Chris H ^a   Woo, Savio L C ^a   Shaker, Mohammed ^a   Thompson, Timothy C ^a  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

Androgen ablation; Gene therapy; Prostate cancer

Indexed keywords

ANDROGEN; ANTIMETABOLITE; GANCICLOVIR; THYMIDINE KINASE;

ADENOVIRUS; ANIMAL; APOPTOSIS; ARTICLE; CASTRATION; CELL CULTURE; GENE THERAPY; GENE VECTOR; GENETICS; HERPES SIMPLEX VIRUS; MALE; MOUSE; MULTIMODALITY CANCER THERAPY; NEOPLASM; NICK END LABELING; PHYSIOLOGY; PROSTATE TUMOR; SURVIVAL; TIME;

ADENOVIRIDAE; ANDROGENS; ANIMALS; ANTIMETABOLITES; APOPTOSIS; CASTRATION; COMBINED MODALITY THERAPY; GANCICLOVIR; GENE THERAPY; GENETIC VECTORS; IN SITU NICK-END LABELING; MALE; MICE; NEOPLASMS, HORMONE-DEPENDENT; PROSTATIC NEOPLASMS; SIMPLEXVIRUS; SURVIVAL; THYMIDINE KINASE; TIME FACTORS; TUMOR CELLS, CULTURED;

EID: 0032618858     PISSN: 09291903     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.cgt.7700004     Document Type: Article

References (50)

1. Eastham JA, Chen S-H, Sehgal I, et al. Prostate cancer gene therapy: herpes simplex virus thymidine kinase gene transduction followed by ganciclovir in mouse and human prostate models. Hum Gene Ther. 1996;7:515-523.
2. Hall SJ, Mutchnik SE, Chen S-H, Woo SLC, Thompson TC. Adenovirus-mediated herpes simplex virus thymidine kinase gene and ganciclovir therapy leads to systemic activity against spontaneous and induced metastasis in an orthotopic model of prostate cancer. Int J Cancer. 1997; 70:183-187.
3. Mootlen FL. Tumor chemosensitivity conferred by inserted thymidine kinase genes: paradigm for a prospective cancer control study. Cancer Res. 1986;46:5276-5281.
4. Freeman SM, Abboud CN, Whartenby KA, et al. The "bystander effect": tumor regression when a fraction of the tumor mass is genetically modified. Cancer Res. 1993;53: 5274-5283.
5. Bi WL, Parysek LM, Warnick R, Stambrook PJ. In vitro evidence that metabolic cooperation is responsible for the bystander effect observed with HSV-tk retroviral gene therapy. Hum Gene Ther. 1993;4:725-731.
6. Elshami AA, Saavcdra A, Zhang H, et al. Gap junctions play a role in the "bystander effect" of the herpes simplex virus thymidine kinase/ganciclovir system in vitro. Gene Ther. 1996;3:85-92.
7. Hamel W, Magnelli L, Chiarugi VP, Israel MA. Herpes simplex virus thymidine kinase/ganciclovir-mediated apoptotic death of bystander cells. Cancer Res. 1996;56:2697-2702.
8. Mesnil M, Piccoli C, Tiraby G, Willecke K, Yamasaki H. Bystander killing of cancer cells by herpes simplex virus thymidine kinase gene is mediated by connexins. Proc Natl Acad Sci USA. 1996;93:1831-1835.
9. Colombo BM, Benedetti S, Ottolenghi S, et al. The "bystander effect": association of μ-87 cell death with ganciclovir-mediated apoptosis of nearby cells and the lack of effect in athymic mice. Hum Gene Ther. 1995;6:763-772.
10. Ram Z, Walbridge S, Shawker T, Culver KW, Blaese RM, Oldfield EH. The effect of thymidine kinase transduction and ganciclovir therapy on tumor vasculature and growth of 9L gliomas in rats. J Neurosurg. 1994;81:256-260.
11. Barba D, Hardin J, Sadelain M, Gage FH. Development of antitumor immunity following thymidine kinase-mediated killing of experimental brain tumors. Proc Natl Acad Sci USA. 1994;91:4348-4352.
12. Vile RG, Nelson JA, Castleden S, Chong H, Hart IR. Systemic gene therapy of murine melanoma using tissue-specific expression of the HSV-tk gene involves an immune component. Cancer Res. 1994;54:6228-6234.
13. Whartenby KA, Abboud CN, Marrogi AJ, Ramesh R, Freeman SM. The biology of cancer gene therapy. Lab Invest. 1995;72:131-145.
14. Wilson KM, Stambrook PJ, Bi WL, Pavelic ZR, Pavelic L, Gluckman JL. HSV-tk gene therapy in head and neck squamous cell carcinoma. Arch Otolaryngol Head Neck Surg. 1996;122:746-749.
15. Gandeep S, Brew R, Green B, et al. Prodrug-activated gene therapy: involvement of an immunological component in the "bystander effect." Cancer Gene Ther. 1996;3: 83-88.
16. Kozlowski JM, Ellis WJ, Grayhack JT. Advanced prostatic carcinoma: early versus late endocrine therapy. Urol Clin N Am. 1991;18:15-24.
17. Pilepich MV, John MJ, Krall JM, McGowan D, Hwang YS, Perez CA. Phase II radiation therapy oncology group study of hormonal cytoreduction with flutamide and zoladex in locally advanced carcinoma of the prostate treated with definitive radiotherapy. Am J Clin Oncol. 1990;13: 461-464.
18. Shearer RJ, Davies JH, Gelister JSK, Dearnaley DP. Hormonal cytoreduction and radiotherapy for carcinoma of the prostate. Br J Urol. 1992;69:521-524.
19. LaBrie F, Dupon TA, Cusan L, et al. Downstaging of localized prostate cancer by neoadjuvant therapy with flutamide and Iupron: the first controlled and randomized trial. Clin Invest Med. 1993;16:499-509.
20. Hanks GE, Hanlon A, Schultheiss T, Corn B, Shipley WU, Lee WR. Early prostate cancer: the national results of radiation treatment from the patterns of care and radiation therapy oncology group studies with prospects for improvement with conformal radiation and adjuvant androgen deprivation. J Urol. 1994;152:1775-1780.
21. Zelefsky MJ, Leibel SA, Burman CM, et al. Neoadjuvant hormonal therapy improves the therapeutic ratio in patients with bulky prostatic carcinoma treated with three-dimensional conformal radiation therapy. Int J Radiat Oncol Biol Phys. 1994;29:755-761.
22. Soloway MS, Sharifi R, Wajsman Z, McLeod D, Wood DP, Puras-Baez A. Randomized prospective study comparing radical prostatectomy alone versus radical prostatectomy preceded by androgen blockade in clinical stage B2 (T2bNxMO) prostate cancer. J Urol. 1995;154:424-428.
23. Van Poppel H, De Ridder D, Elgamal AA, et al. Neoadjuvant hormonal therapy before radical prostatectomy decreases the number of positive surgical margins in stage T2 prostate cancer: interim results of a prospective randomized trial. J Urol. 1995;154:429-434.
24. Berges RR, Furuya Y, Remington L, English HF, Jacks T, Isaacs JT. Cell proliferation, DNA repair, and p53 function are not required for programmed death of prostatic glandular cells induced by androgen ablation. Proc Natl Acad Sci USA. 1993;90:8910-8914.
25. Montironi R, Magi-Galluzzi C, Muzzongri G, Prete E, Polito M, Fabris G. Effects of endocrine treatment on normal prostate, prostatic intraepithelial neoplasia, and prostatic adenocarcinoma. J Clin Pathol. 1994;47:906-913.
26. Montironi R, Galluzzi MG, Marina S, Diamanti L. Quantitative characterization and location of cell proliferation and death in prostate pathology. J Cell Biochem. 1994;S19: 238-245.
27. Furuya Y, Lin XS, Walsh JG, Nelson WG, Isaacs JT. Androgen ablation-induced programmed death of prostatic glandular cells does not involve recruitment into a defective cell cycle or p53 induction. Endocrinology. 1995; 136:1898-1905.
28. Samejima Y, Meruelo D. "Bystander killing" induces apoptosis and is inhibited by forskolin. Gene Ther. 1995;2: 50-58.
29. Thompson TC, Southgate J, Kitchener G, Land H. Multistage carcinogenesis induced by ras and myc oncogenes in a reconstituted model. Cell. 1989;56:917-930.
30. Thompson TC, Egawa S, Kadmon D, et al. Androgen sensitivity and gene expression in ras + myc-induced mouse prostate cancers. J Steroid Biochem Mol Biol 1992; 43:79-85.
31. Baley PA, Yoshida K, Qian W, Sehgal I, Thompson TC. Progression to androgen insensitivity in a novel in vitro mouse model for prostate cancer. J Steroid Biochem Mol Biol. 1995;52:403-413.
32. Chen S-H, Shine HD, Goodman JC, Grossman RG, Woo SLC. Gene therapy for brain tumors: regression of experimental gliomas by adenovirus-mediated transfer in vivo. Proc Natl Acad Sci USA. 1994;91:3054-3057.
33. Perez-Cruet MJ, Trask TW, Chem S-H, et al. Adenovirusmediated gene therapy of experimental gliomas. J Neurosci Res. 1994;39:506-511.
34. Stratford-Pericaudet LD, Makeh I, Pericaudet M, Briand P. Widespread long-term gene transfer to mouse skeletal muscles and heart. J Clin Invest. 1992;90:626-630.
35. Graham F, Prevec L. Manipulation of adenoviral vectors. In: Murray EJ, ed. Methods in Molecular Biology: Gene Transfer and Expression Protocols, Vol 7. Clifton, NJ: Humana Press; 1991:109-128.
36. Janik P, Briand P, Hatmann NR. The effect of estroneprogesterone treatment on cell proliferation kinetics of hormone-dependent GR mouse mammary tumors. Cancer Res. 1975;35:3698-3704.
37. Cool V, Pirotte B, Gerard C, et al. Curative potential of herpes simplex virus thymidine kinase gene transfer in rat with 9L gliosarcoma. Hum Gene Ther. 1996;7:627-635.
38. Gavrielli Y, Sherman Y, Ben-Sasson SA. Identification of programmed cell death in situ via specific labeling of nuclear DNA fragmentation. J Cell Biol. 1992;119:493-501.
39. Bonnekoh B, Greenhalgh DA, Bundman DS, et al. Inhibition of melanoma growth by adenoviral-mediated HSV thymidine kinase gene transfer in vivo. J Invest Dermatol. 1995;104:313-317.
40. Chen S-H, Chen XHL, Wang Y, et al. Combination gene therapy for liver metastasis of colon carcinoma in vivo. Proc Natl Acad Sci USA. 1995;92:2577-2581.
41. O'Malley BW, Jr, Chen S-H, Schwartz MR, Woo SLC. Adenovirus-mediated gene therapy for head and neck squamous cell cancer in a nude mouse model. Cancer Res. 1995;55:1080-1085.
42. Elshami AA, Kucharczuk JC, Zhang HB, et al. Treatment of pleural mesothelioma in an immunocompetent rat model utilizing adenoviral transfer of the herpes simplex virus thymidine kinase gene. Hum Gene Ther. 1996;7:141-148.
43. Tong X-W, Block A, Chen S-H, et al. In vivo gene therapy of ovarian cancer by adenovirus-mediated thymidine kinase gene transduction and ganciclovir administration. Gynecol Oncol. 1996;61:175-179.
44. Yee D, McGuire SE, Brunner N, et al. Adenovirus-mediated gene transfer of herpes simplex virus thymidinekinase in an ascites model of human breast cancer. Hum Gene Ther. 1996;7:1251-1257.
45. Zeitman AL, Prince EA, Nakfoor BM, Shipley WU. Permanent tumor eradication by radiation is enhanced by prior androgen withdrawal in two experimental models. J Urol. 1996;155:509a.
46. Grossman CJ. Interactions between the gonadal steroids and the immune system. Science. 1985;227:257-261.
47. Utsuyama M, Hirokawa K. Hypertrophy of the thymus and the restoration of immune functions in mice and rats by gonadectomy. Mech Aging Dev. 1989;47:175-185.
48. Rife SU, Marquez MG, Escalante A, Velich T. The effect of testosterone on the immune response: mechanism of action on antibody-forming cells. Immunol Invest. 1990;19: 259-270.
49. Hartley-Asp B, Vukanovic J, Joseph IBJK, Strandgarden K, Polacek J, Isaacs JT. Anti-androgenic treatment with linomide as an adjuvant to surgical castration in experimental prostate cancer. J Urol. 1997;158:902-907.
50. Joseph IBJK, Nelson JB, Denmeade SR, Isaacs JT. Androgens regulate vascular endothelial growth factor content in normal and malignant prostatic tissue. Clin Cancer Res. 1997;3:2507-2511.